Compounded Semaglutide for Patients With PCOS and Weight or Insulin-Resistance Concerns
Highland Longevity prescribes compounded semaglutide — not Wegovy or Ozempic. Semaglutide as a molecule is used in brand-name products manufactured by Novo Nordisk for chronic weight management and type 2 diabetes; the compounded version Highland prescribes is not FDA-approved. For patients with PCOS who have weight or insulin-resistance concerns, compounded semaglutide may be considered as part of a comprehensive care plan. Semaglutide is not approved specifically for PCOS, and individual treatment decisions are made by your physician.
How Semaglutide Is Considered in PCOS Care
PCOS is heterogeneous, and no medication choice or outcome should be assumed from the diagnosis alone.
Metabolic Evaluation
PCOS may coexist with insulin resistance and other metabolic concerns. Laboratory findings and treatment options are individualized rather than inferred from the diagnosis alone.
Body-Composition Monitoring
DEXA may be used to estimate fat mass, lean mass, and regional distribution over time; medication cannot target one body area or guarantee a specific change.
Controls Cravings
Appetite and food-related symptoms vary in PCOS. Response, adverse effects, and nutrition needs are reviewed over time without a promised outcome.
The Science Behind GLP-1s and PCOS
PCOS is heterogeneous, and weight concerns can reflect several interacting factors. A complete evaluation considers metabolic health, symptoms, medications, sleep, nutrition, activity, and reproductive plans.
Semaglutide acts at GLP-1 receptors and can delay gastric emptying. It is not approved specifically to treat PCOS, and outcomes from FDA-approved products do not establish the safety, effectiveness, quality, or expected results of Highland's compounded formulation.
Whether treatment is appropriate depends on the weight-management indication, metabolic health, medical history, contraindications, current medications, reproductive plans, risks, access, and goals.
- Weight, waist, and body-composition trends when useful
- Symptoms, adverse effects, and medication tolerance
- Nutrition, resistance training, activity, and sleep
- Reproductive plans and clinically indicated metabolic markers
What We Monitor Beyond Weight
PCOS symptoms and reproductive outcomes have multiple causes. When clinically relevant, Highland follows these separately without promising that a weight-management medication will improve them:
- Menstrual and ovulatory patterns when relevant
- Symptoms such as acne or excess hair when relevant
- Cycle changes over time
- Clinically indicated metabolic markers
- Other symptoms or laboratory findings when clinically indicated
Because semaglutide's brand-name indications (Wegovy, Ozempic) include weight management and type 2 diabetes — both of which address insulin sensitivity — patients with PCOS and co-occurring weight or metabolic concerns may benefit from the molecule. Highland Longevity prescribes compounded semaglutide, which is not FDA-approved, and we do not dispense Wegovy or Ozempic. Semaglutide is not approved specifically for PCOS, and it is not a cure for PCOS. Treatment decisions require individual clinical evaluation.
PCOS Requires Individualized Care
PCOS-related weight concerns deserve evaluation without blame or a one-cause explanation. Highland reviews metabolic health, symptoms, medications, nutrition, activity, sleep, reproductive plans, and treatment risks before recommending any option.
— Dr. Josh Lindsley, DO, DABOM
Semaglutide for PCOS FAQs
No. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Wegovy, Ozempic, or Rybelsus. Compounded medications are not FDA-approved.
PCOS is heterogeneous and semaglutide is not approved specifically to treat PCOS. Whether any semaglutide product is appropriate depends on the weight-management indication, metabolic health, medical history, contraindications, current medications, reproductive plans, risks, access, and goals. Highland's compounded formulation is not FDA-approved.
No improvement in menstrual patterns, androgen-related symptoms, fertility, or metabolic markers is guaranteed. These outcomes have multiple causes and are monitored separately when clinically relevant.
Semaglutide should not be used during pregnancy. Current product labeling advises stopping semaglutide at least two months before a planned pregnancy. Pregnancy plans and contraception should be reviewed with the prescribing clinician.
Weight-loss outcomes vary by medication, dose, duration, adherence, health conditions, and patient. Published studies do not establish expected outcomes for Highland's compounded formulation or for an individual patient; no amount or timeline is guaranteed. DEXA may be used to estimate changes in fat mass and lean mass over time.
Neither medication is approved specifically to treat PCOS. Choice depends on the weight-management indication, medical history, contraindications, current medications, reproductive plans, tolerability, access, risks, and goals. Approved-product trials do not establish outcomes for Highland's compounded formulations.
Weight regain can occur after treatment changes. The plan is reassessed over time based on benefit, risk, adverse effects, nutrition, activity, body-composition estimates when useful, access, and patient goals; no maintenance outcome is guaranteed.
Serving Fort Worth & Surrounding Communities
Our clinic is conveniently located in the Fort Worth Alliance area, just minutes from communities throughout the DFW metroplex.
Located at 4801 Golden Triangle Blvd Suite 121, Fort Worth, TX 76244
Ready for a Treatment That Understands PCOS?
Book a free consultation to discuss how semaglutide can help you finally lose weight—by addressing the insulin resistance driving your symptoms.
Compounded medication disclaimer: Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Wegovy®, Ozempic®, Rybelsus®, or any other brand-name semaglutide product manufactured by Novo Nordisk.
Compounded semaglutide is prepared by a state-licensed compounding pharmacy under the supervision of our physician. Compounded medications are not FDA-approved. They are permitted under federal law when an FDA-approved product cannot meet the patient's clinical needs, or when the FDA designates a shortage. Your physician will discuss the implications, risks, and benefits of compounded therapy at your consultation.